王增武
作者单位：102308 北京，中国医学科学院阜外医院 国家心血管病中心社区防治部
通信作者：王增武，电子信箱：wangzengwu@foxmail.com
引用本文：
王增武. 《中国高血压防治指南(2024年修订版)》更新要点解读[J]. 中国心血管杂志, 2024, 29(5): 391-395. DOI: 10.3969/j.issn.1007-5410.2024.05.001.
2024年8月11日，《中国高血压防治指南(2024年修订版)》(简称"新指南")正式发布，并同步发表[1]。自2022年开始，中国高血压防治指南修订委员会在2018年版指南[2]的基础上，进行了多次会议讨论对指南进行更新修订，纳入了国内外高血压及相关疾病领域最新研究进展，充分体现了近年高血压领域的防治理念、现行政策与防治方法的进展，具有鲜明的中国特色。新指南对部分既往内容进行了大篇幅更新，包括我国人群高血压重要危险因素、血压测量和高血压治疗等(表1)。本文就此部分更新的内容进行解读。
高血压治疗
1 生活方式干预
2 高血压的药物治疗
3 高血压的器械治疗
参考文献
[1] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文), 2024, 32(7): 603-700.
[2] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56.
[3] 张梅, 吴静, 张笑, 等. 2018年中国成年居民高血压患病与控制状况研究[J]. 中华流行病学杂志, 2021, 42(10): 1780-1789.
[4] Pinkhas D, Ho T, Smith S, et al. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development[J]. Cardiooncology, 2017, 3: 5.
[5] 肖琳, 南奕, 邸新博, 等. 2018年中国15岁及以上人群吸烟现况及变化趋势研究[J]. 中华流行病学杂志, 2022, 43(6): 811-817.
[6] Li L, Yang A, He X, et al. Indoor air pollution from solid fuels and hypertension: a systematic review and meta-analysis[J]. Environ Pollut, 2020, 259: 113914.
[7] Vinueza Veloz AF, Yaulema Riss AK, De Zeeuw CI, et al. Blood pressure in Andean adults living permanently at different altitudes[J]. High Alt Med Biol, 2020, 21(4): 360-369.
[8] Zhang D, Huang QF, Li Y, et al. A randomized controlled trial on home blood pressure monitoring and quality of care in stage 2 and 3 hypertension[J]. Hypertens Res, 2021, 44(5): 533-540.
[9] Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death[J]. N Engl J Med, 2021, 385(12): 1067-1077.
[10] Yuan Y, Jin A, Neal B, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial[J]. Nat Med, 2023, 29(4): 973-981.
[11] Xu A, Ma J, Guo X,et al. Association of a province-wide intervention with salt intake and hypertension in Shandong province, China, 2011-2016[J]. JAMA Intern Med, 2020, 180(6): 877-886.
[12] Wang Y, Feng L, Zeng G, et al; DECIDE-Diet Study Group. Effects of cuisine-based Chinese heart-healthy diet in lowerin g blood pressure among adults in China: multicenter, single-blind, randomized, parallel controlled feeding trial[J]. Circulation, 2022, 146(4): 303-315.
[13] Wang C, Fu W, Cao S, et al. Association of adiposity indicators with hypertension among Chinese adults[J]. Nutr Metab Cardiovasc Dis, 2021, 31(5): 1391-1400.
[14] 陈祚, 李苏宁, 王馨, 等. 我国中年人群高血压、超重和肥胖的发病率及其与心血管事件的关系[J]. 中华心血管病杂志, 2020, 48(1): 47-53.
[15] Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials[J]. PLoS One, 2015, 10(3): e0121993.
[16] Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial[J]. Lancet, 2022, 400(10361): 1417-1425.
[17] Zhang W, Zhang J, Yan J, et al. Efficacy and safety of sacubitril/ allisartan for the treatment of primary hypertension: a phase 3 randomized, double-blind study[J]. J Am Coll Cardiol, 2024, 83(13): Suppl. 1705.
[18] Lin DS, Wang TD, Buranakitjaroen P, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe[J]. J Clin Hypertens (Greenwich), 2021, 23(3): 556-567.
[19] Geng Q, Yan R, Wang Z, et al. Effects of LCZ696 (sacubitril/valsartan) on blood pressure in patients with hypertension: a meta-analysis of randomized controlled trials[J]. Cardiology, 2020, 145(9): 589-598.
[20] Zhang DY, Cheng YB, Guo QH, et al. Treatment of masked hypertension with a Chinese herbal formula: a randomized, placebo-controlled trial[J]. Circulation, 2020, 142(19): 1821-1830.
[21] Lai X, Dong Z, Wu S, et al. Efficacy and safety of Chinese herbal medicine compared with losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial[J]. Circ Cardiovasc Qual Outcomes, 2022, 15(3): e007923.
[22] Bhatt DL, Vaduganathan M, Kandzari DE, et al; SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomized SYMPLICITY HTN-3 trial[J]. Lancet, 2022, 400(10361): 1405-1416.
[23] Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham controlled trial[J]. Lancet, 2022, 399(10333): 1401-1410.
